Abstract
Levosimendan is a calcium-sensitizing agent that improves cardiac function, hemodynamic performance, and survival in critically ill adult patient. Few data exist on its off-label use in paediatric patients. We therefore performed a systematic review updated in September 2013 of all the published articles describing the use of levosimendan in paediatric patients. We identified 24 studies published in the period 2004-2013 that included a total of 623 patients, the largest one being a case series of 293 patients. Most of the patients underwent cardiac surgery, other settings consisting of chronic heart failure, primary congenital heart diseases and sepsis and cancer-associated cardiac dysfunction. Most studies reported improvement in ventricular function, central venous oxygen saturation, serum lactate levels or cardiac index. The 5 randomized studies published so far have all been performed in cardiac surgery and suggest a beneficial effect on hemodynamic data with no effect on intensive care unit stay, hospital stay or survival. Side effects (e.g. hypotension) were reported. This inodilator merits to be investigated with further randomized trials focusing on clinically relevant outcomes.
Keywords: Cardiac surgery, chronic heart failure, congenital heart diseases, hemodynamic effect, levosimendan, paediatric patients, systematic review.
Current Vascular Pharmacology
Title:A Systematic Review on Levosimendan in Paediatric Patients
Volume: 13 Issue: 1
Author(s): Simona Silvetti, Paolo Silvani, Maria Luisa Azzolini, Roberto Dossi, Giovanni Landoni and Alberto Zangrillo
Affiliation:
Keywords: Cardiac surgery, chronic heart failure, congenital heart diseases, hemodynamic effect, levosimendan, paediatric patients, systematic review.
Abstract: Levosimendan is a calcium-sensitizing agent that improves cardiac function, hemodynamic performance, and survival in critically ill adult patient. Few data exist on its off-label use in paediatric patients. We therefore performed a systematic review updated in September 2013 of all the published articles describing the use of levosimendan in paediatric patients. We identified 24 studies published in the period 2004-2013 that included a total of 623 patients, the largest one being a case series of 293 patients. Most of the patients underwent cardiac surgery, other settings consisting of chronic heart failure, primary congenital heart diseases and sepsis and cancer-associated cardiac dysfunction. Most studies reported improvement in ventricular function, central venous oxygen saturation, serum lactate levels or cardiac index. The 5 randomized studies published so far have all been performed in cardiac surgery and suggest a beneficial effect on hemodynamic data with no effect on intensive care unit stay, hospital stay or survival. Side effects (e.g. hypotension) were reported. This inodilator merits to be investigated with further randomized trials focusing on clinically relevant outcomes.
Export Options
About this article
Cite this article as:
Silvetti Simona, Silvani Paolo, Azzolini Maria Luisa, Dossi Roberto, Landoni Giovanni and Zangrillo Alberto, A Systematic Review on Levosimendan in Paediatric Patients, Current Vascular Pharmacology 2015; 13 (1) . https://dx.doi.org/10.2174/1570161112666141127163536
DOI https://dx.doi.org/10.2174/1570161112666141127163536 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?
Current Pharmaceutical Design Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure
Current Pharmaceutical Design At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Editorial: The Need of Time: Development of New Antimicrobials
Current Topics in Medicinal Chemistry New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Interleukin-1 and Occlusive Arterial Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer’s Disease: The Shanghai Aging Study
Current Alzheimer Research Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies
Current Vascular Pharmacology The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Formation and Structure of a Novel Nitration Product of δ -Tocopherol
Current Organic Synthesis